Skip to search formSkip to main contentSkip to account menu

0.5 ML lanreotide 240 MG/ML Prefilled Syringe

Known as: lanreotide 120 MG in 0.5 ML Prefilled Syringe, LANREOTIDE 120MG SA SUSP INJ SYRINGE, LANREOTIDE 120MG INJ,SUSP,SA SYRINGE [VA Product] 
National Institutes of Health

Related topics

Related topics

7 relations

Narrower (1)

0.5 ML lanreotide 240 MG/ML Prefilled Syringe [Somatuline]

Broader (1)

Pituitary Hormones, Anterior
Prefilled SyringeSomatostatinanalogs & derivativeslanreotide

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
Effects of a long-acting somatostatin analogue, lanreotide, on bile duct ligation-induced liver fibrosis in rats.
BACKGROUND/AIMS Somatostatin receptors have been shown on hepatic stellate cells, and somatostatin infusion has been shown to… 
2010
2010
Effects of a long-acting somatostatin analogue, lanreotide, on bile duct ligation-induced liver fibrosis in rats Uzun etkili somatostatin analou, lanreotidin s›çanlarda safra yolu balanarak…
Highly Cited
2010
Highly Cited
2010
Elucidation of the self-assembly pathway of lanreotide octapeptide into beta-sheet nanotubes: role of two stable intermediates.
Nanofabrication by molecular self-assembly involves the design of molecules and self-assembly strategies so that shape and… 
2009
2009
Population Pharmacokinetic Analysis of Lanreotide Autogel® in Healthy Subjects
Background and objectiveLanreotide is a somatostatin analogue used for the treatment of acromegaly and neuroendocrine tumours… 
2008
2008
Gluteal nodules in patients with metastatic midgut carcinoid disease treated with depot somatostatin analogs.
CONTEXT AND OBJECTIVES We were referred a patient with metastatic well-differentiated endocrine tumor of the small intestine… 
Highly Cited
2006
Highly Cited
2006
Efficacy of lanreotide Autogel® administered every 4–8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial
Objective and design  Depot somatostatin analogues are well accepted as either adjuvant or primary therapy for acromegaly, and… 
2005
2005
Pharmacokinetics and population pharmacodynamic analysis of lanreotide Autogel.
2005
2005
Changes in the expression of somatostatin receptor imaging following Y-90 lanreotide therapy for carcinoid tumor: a flare response?
A 53-year-old man with In-111 octreotide-positive metastatic hepatic carcinoid was referred for Y-90 lanreotide therapy. A… 
1999
1999
Intraoperative Gamma Detection Of125I-Lanreotide in Women With Primary Breast Cancer
Background: Somatostatin receptors are present in most human breast cancers. We performed a pilot trial of intraoperative tumor… 
Highly Cited
1998
Highly Cited
1998
Indium-111-DOTA-lanreotide: biodistribution, safety and radiation absorbed dose in tumor patients.
UNLABELLED Imaging with radiolabeled somatostatin/vasoactive intestinal peptide analogs has recently been established for the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)